



# Valiant Organics Limited

Date: July 01,2022

To,  
Listing/Compliance Department  
**BSE LTD**  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001.

**BSE CODE-540145**

To,  
Listing/Compliance Department  
**National Stock Exchange of  
India Limited**  
"Exchange Plaza", Plot No.C/1,  
G Block Bandra-Kurla Complex,  
Bandra (E), Mumbai- 400 051.  
**NSE CODE- VALIANTORG**

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, please find enclosed herewith Valiant Organics Limited Investor Presentation- July 2022.

A copy of aforesaid Investor Presentation is also hosted on the website of company [www.valiantorganics.com](http://www.valiantorganics.com)

Kindly take the same on your record and acknowledge.

Thanking You,

Yours Faithfully,

**For Valiant Organics Limited**


*Avani!*

Avani D. Lakahni

**Company Secretary**

ICSI M.NO.: A47118






# **Valiant Organics** Limited

Investor Presentation | July - 2022

# SNAPSHOT



One of the largest chlorophenol derivatives manufacturer globally



One of the leading manufacturer of Benzene derivatives products



One of the largest domestic PNA manufacturer



One of the few commercial players in Ortho Anisidine and Para Anisidine



Amongst 1st few domestic PAP Manufacturers



Diversified client base across Pharmaceuticals, Dyes & Pigments, Agrochemicals and specialty chemicals.



6 Manufacturing units across 5 Locations




5 Zero Liquid Discharge plants



Total Production Capacity of 70,000 TPA




850+ Employees




# COMPANY OVERVIEW

- Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India.
- The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmaceuticals, dyes, pigments, and veterinary medications.
- Key chemistries include Chlorination, Hydrogenation, Ammonolysis, Acetylation, Sulphonation, Methoxylation amongst others.
- Over the years the company has primarily focused on manufacturing specialty chemicals that have a high demand but low supply and are primarily dependent on imports.
- The company is listed on both the BSE and NSE with a market capitalization of INR 24,983 Mn as on 31<sup>st</sup> March, 2022.


Operating Revenue (INR Mn) and EBITDA Margin (%)



FY22 Revenue Break-up – Chemistries



FY21 Revenue Break-up – End user Industry







**Shri Velji K. Gogri – Chairman, Independent Director**

Chemical Engineer having 37 years of experience in the chemical industry, graduated from IIT Mumbai. A number of manufacturing units for bulk pharmaceuticals, intermediates, and fine chemicals have been established by him. Has a thorough understanding of chemical processes, equipment, and chemical safety.



**Shri Arvind K. Chheda - Managing Director**

Holds an accounting diploma from the government. He has over two decades of expertise in this domain. He is also one of the company's main promoters. He is responsible for building the corporate set up and moving the company's corporate structure forward.



**Shri Mulesh M. Savla - Independent Director**

He is a practicing Chartered Accountant and a Partner in Shah & Savla LLP, Chartered Accountant. Has vast experience of more than 30 years in Taxation, Accounts and Finance, structuring, restructuring of entities.



**Dr. Kiritkumar H. Desai – Non-Executive Director**

Sr. Vice President at Aarti Industries Limited, heading product development and quality. Has in-depth experiences setting up and growing the R&D as well as quality control function for more than thirty two years in chemical and pharma Industries. Developed more than 200 products during this journey.



**Shri Mahek M. Chheda – Chief Financial Officer & Executive Director**

Holds a BSC Business graduate from college affiliated with University of London. He also has more than 7 years of work experience in the field of Finance, Marketing and Business Development.



**Shri Vishnu J. Sawant – Executive Director**

Has nearly 3 decades of experience of working with Chemical Manufacturing companies. He is currently responsible for running the entire operations of the Company at the Factory level.



**Shri Sathiababu K. Kallada - Executive Director**

He has an experience of more than 35 years in the field of Chemical Industry and has acted at responsible positions at Aarti Industries Limited



**Shri Nemin Savadia – Executive Director**

He has been in the field of Chemical Industry for the last 25 years and manages the Business Administration of Tarapur Plant.



**Shri Siddharth Shah – Executive Director**


He is a Bachelor in Chemical Engineering & has done MBA in Global Business from Scotland, Heriott Watt University. He has a vast experience of around 15 years in the field of Chemicals and his vast experience also includes production, factory admin, Project Management, operations and process development in the Chemical industry.



**Shri Santosh S Vora – Non -Executive Director**

He is a Post Graduate in Family Business from Indian School of Business, Hyderabad, having experience of around 7 years in chemical and pharmaceutical industry. Presently, he is acting as the Managing Director of Valiant Laboratories Limited.

# Key Milestones





Aarti Industries



SALTIGO GmbH  
(Lanxess Group)



Anupam Rasayan  
India Ltd.



Lanxess India Private  
Limited



Shiv Corporation  
(Prop-Jenil  
Enterprise Pvt. Ltd.)



Kisco Ltd.



Clariant Chemicals  
(India) Ltd.



Spectrum Dyes &  
Chemicals Pvt. Ltd.




Supreet Chemical  
Pvt. Ltd.




Kumar Organic Products Limited  
Ingredients for us

Kumar Organic  
Products Limited








# Capex Projects

Product	Installed Capacity (MT per month)	Approx. Capex (INR Mn)	Project Status	Remarks
<b>Commissioned</b>				
Para Nitro Aniline (PNA) & Ortho Chloro Para Nitro Aniline (OCPNA)	550	~ 70	Completing phase-wise	<ul style="list-style-type: none"> <li>Expansion from 550 TPM to 750 TPM at Vapi plant</li> <li>Full capacity addition in progress</li> </ul>
Ortho Nitro Anisole (ONA)	600	~ 350-400	Completed in Q4 FY'20	<ul style="list-style-type: none"> <li>Backward integrated for existing product Ortho Anisidine</li> </ul>
Para Nitro Anisole (PNA)	200		Completed in Q4 FY'20	<ul style="list-style-type: none"> <li>Captive use towards manufacture of Para Anisidine</li> </ul>
Para Anisidine (PA)	150		Completed in Q4 FY'20	<ul style="list-style-type: none"> <li>Currently mostly being imported in India</li> <li>Valiant will be one of the major producers in India</li> </ul>
<b>Ongoing Projects</b>				
Para Amino Phenol (PAP)	1,000	~ 2,200	Completed in Q4 FY'21	<ul style="list-style-type: none"> <li>Currently, limited availability domestically and mostly imported</li> <li>Due to technical difficulties in achieving the desired specification, the actual production delayed</li> <li>Ramp up in process for batch operations on-going.</li> <li>Simultaneous work on-going towards continuous process</li> </ul>
Ortho Amino Phenol (OAP)	100	~ 150	Phase 1 production to commence from Q2 FY'23	<ul style="list-style-type: none"> <li>Currently, entirely imported in India</li> <li>Part of the production will be utilized as forward integration for one of company's existing products</li> <li>Trial run successful</li> </ul>
Pharma Intermediates	20	~ 600	Expected production from Q2 FY'23	<ul style="list-style-type: none"> <li>Multi-purpose plant for forward integration within Group Company</li> <li>Will manufacture N-1, N-2 raw materials for API products</li> <li>Delay due to approvals</li> </ul>



# BUSINESS OVERVIEW

## Ammonolysis

### Key Products:

- Para Nitro Aniline
- Ortho Chloro Para Nitro Aniline

### Industries Served:

- Dyes
- Pigments

## Chlorination

### Key Products:

- Para ChloroPhenol (PCP)
- Ortho ChloroPhenol (OCP)
- 2,4 Di ChloroPhenol (2,4 DCP)
- 2,6 Di ChloroPhenol (2,6 DCP)
- 2,4,6 Tri ChloroPhenol (2,4,6 TCP)

### Industries Served:

- Agro Chemicals
- Cosmetics
- Veterinary
- Pharmaceuticals

## Others

### Acetylation

#### Key Products:

- 6 Acetyl OAPSA
- OA Acetanilide
- PA Acetanilide

### Sulphonation

#### Key Products:

- OT5SA
- 4B Acid
- 2B Acid

### Methoxylation

#### Key Products:

- Ortho Nitro Anisole
- Para Nitro Anisole

### Industries Served:

- Dyes

### Industries Served:

- Dyes
- Pigments

### Industries Served:

- Dyes
- Pigments


## Hydrogenation

### Key Products:

- Ortho Anisidine
- Para Anisidine
- IPPCA
- Meta Chloro Aniline
- Para Amino Phenol
- Ortho Amino Phenol

### Industries Served:

- Dyes
- Pigments
- Pharmaceutical
- Agro Chemicals



FY22 Revenue Share



Any reaction in which chlorine or chlorine compounds are introduced into a molecule to obtain the desired outcome is known as chlorination.

- Valiant is the only domestic player and also a global leader in Chlorophenol products with ~25% global market share.
- The company has over two-decade experience in Chlorophenols, with long-term relationships with global marquee customers due to their high-quality products and efficient supply chain management.
- The Sarigram plant of the company is dedicated for the chlorination process, with a capacity of 18,000 MTPA, and a Zero Liquid Discharge facility and highly automated Distributed Control Systems significantly reducing manual interventions.
- More than 50% of sales come from export markets.


## Key Products:

- Para ChloroPhenol (PCP)
- Ortho ChloroPhenol (OCP)
- 2,4 Di Chlorophenol (2,4 DCP)
- 2,6 Di ChloroPhenol (2,6 DCP)
- 2,4,6 Tri ChloroPhenol (2,4,6 TCP)


## Industries Served:

- Agro Chemicals
- Cosmetics
- Veterinary
- Pharmaceuticals

## Revenues (INR Mn)\*



## Sales Volumes (MT)



\*Revenue figures are on Standalone basis

Ammonolysis is a high-pressure chemical reaction done in an autoclave where ammonia is used as a reactant.

- Valiant developed Ammonolysis capabilities as a result of its two acquisitions. i.e. Abhilasha Tex Chem Pvt. Ltd. in 2017 & Amarjyot Chemicals Ltd. in 2019.
- The company has an approximately 15,600 MTPA capacity for this process, making it one of the largest players in the domestic market.
- Valiant has two dedicated manufacturing facilities located at Tarapur and Vapi to carry out the ammonolysis process.
- The company supplies its products to almost all the leading Dye manufacturers in the country, and has a leadership position in manufacturing PNA due to its raw material security of PNCB from group company, Aarti Industries.


## Key Products:

- Para Nitro Aniline (PNA)
- Ortho Chloro Para Nitro Aniline


## Industries Served:

- Dyes
- Pigments

## Revenues (INR Mn)\*



## Sales Volumes (MT)



\*Revenue figures are on Standalone basis

Hydrogenation is a chemical reaction between molecular hydrogen (H<sub>2</sub>) and another compound or element, usually in the presence of a catalyst.

- The company has manufacturing facilities in Jhagadia for Hydrogenation. The first unit (also named as Unit 1) has a capacity of 27,000 MTPA which became a part of Valiant Organics through the amalgamation of Amarjyot Chemicals in 2019.
- It has also ventured into the manufacturing of 2 new products in FY21 of Ortho Anisidine (OA) and Para Anisidine (PA), as well as expanded the capacity of a couple of existing products.
- The company also does contract manufacturing for a few leading domestic clients for some key customized products from these plants.

**Para Amino Phenol (PAP) is an essential element in the synthesis of paracetamol.**

- PAP is a difficult product to make and is primarily an import substitute product in India.
- Due to the company's strong experience and significant efforts on R&D, as well as raw material security of PNCB from its group company, Aarti Industries Ltd, it became one of the first companies in India to commercialize the plant for manufacturing Para Amino Phenol (PAP) in FY21 in Jhagadia Unit 2 with a capacity of 12,000 MTPA.
- Being a difficult product to manufacture, the company is currently focusing on achieving process consistencies and expect ramp of production in FY23.
- Majority of its PAP production will be sold to Valiant Laboratories Ltd, which is the subsidiary of the company.

### Key Products:


- Ortho Anisidine
- Para Anisidine
- IPPCA
- Meta Chloro Aniline
- Ortho Amino Phenol
- Para Amino Phenol

### Industries Served:


- Dyes
- Pigments
- Pharmaceuticals
- Agro Chemicals

*\*Revenue figures are on Standalone basis*

**Revenues (INR Mn)\***



**Sales Volumes (MT)**



## Acetylation

Acetylation is a chemical reaction which introduces an acetyl functional group into a chemical compound.

- The acetylation procedure is carried out at the company's Ahmedabad facility which has a capacity of 1,800 MTPA
- The key product under this segment is '6 Acetyl Ortho Aminophenol Para Sulfonic Acid', which finds its usage in dye intermediates.
- Valiant also does job work and helps in multiple conversions on annual contracts.

## Sulphonation


Sulfonation is an organic reaction in which a hydrogen atom on an arene is replaced by a sulfonic acid functional group in an electrophilic aromatic substitution.

- Like acetylation, the sulphonation procedure is also carried out at the company's Ahmedabad facility.
- The products Ortho Toluidine 5 Sulfonic Acid (OT5SA), 2-Amino-5-Methyl benzenesulfonic Acis (4B Acid), & 2-Amino-4-Chloro-5 Methyl Benzenesulfonic Acid (2B Acid) are used as dye and pigment intermediaries.


## Methoxylation

- The products, Ortho Nitro Anisole (ONA) & Para Nitro Anisole (PNA) are being captively consumed to manufacture Ortho Anisidine (OA) and Para Anisidine (PA).
- This process is being carries out along with hydrogenation at Unit 1 of the Jhagadia facility.

Revenues (INR Mn)\*



Sales Volumes (MT)



\*Revenue figures are on Standalone basis




# INDUSTRY OVERVIEW





- The chemicals industry in India covers more than 80,000 commercial products.
- India is 6<sup>th</sup> largest manufacturer of chemicals in the world and 4<sup>th</sup> largest in Asia.
- The Indian chemical industry was pegged at USD 178 billion in FY 2019-20 and is expected to reach USD 300 billion by 2024-25.
- The Asia Pacific (APAC) dominates the specialty chemicals market across the world, with a share of 42%.
- According to recent CRISIL report, Indian manufacturers have recorded a CAGR of 11% in revenue between FY15 and FY21, increasing India's share in the global specialty chemicals market to 4% from 3%.
- A revival in domestic demand and robust exports will spur a 50% YoY increase in the capex of specialty chemicals manufacturers in FY22 to Rs. 6,000-6,200 Crs (USD 815-842 Mn).
- Global demand for chlorophenol is around 60,000MT/y and is expected to grow in high-single digits annually.
- Supply disruption in China has caused the global end-user industries to diversify their vendor base mainly towards Indian players.
- The textiles segment dominated the dyes market with a share of over 62%, in terms of revenue, in 2020. However, the printing inks segment is estimated to register the fastest CAGR from 2021 to 2028.
- Countries, such as India and China, are major producers of dyes, which is likely to provide positive scope for printing inks application across the Asia Pacific region. India is a global supplier of dye, accounting for ~16% of the global production of dyestuffs and dye intermediaries.
- Agrochemicals are the key revenue component of India, which exports 50% of its total production.
- Insecticides share 53% of the total domestic agrochemicals market, followed by Herbicides.

Global Chemical Market (USD Bn)




Indian Chemical Market (USD Bn)





### GROWING DEMAND

- Rise in demand from end-users Industries such as food processing, personal care & home care is driving development of different segments in India's specialty chemical market.
- The domestic chemicals sector's SME's are expected to showcase 18-23% revenue growth in FY22, owing to an improvement in domestic demand and higher realisations.
- Rising middle-class population is likely to support strong demand for specialty chemical in the automotive, personal products, water treatment and construction segments.



### OPPORTUNITIES

- Supply disruption in China has caused the global end-user industries to diversify their vendor base mainly towards Indian players.
- Closure of plants in the EU and China due to increasing environmental concerns have favoured Indian manufacturers to invest further in specialty chemicals.
- With Global companies seeking to de-risk their supply chains, which are dependent on China, the chemical sector in India has the opportunity for a significant growth




### POLICY SUPPORT

- The government plans to introduce production-linked incentives (PLI) scheme to promote domestic manufacturing of agrochemicals.
- Under union budget 2021-2022, the government allocated INR 233.14 Crs (USD 32.2Mn) to the Department of Chemicals and Petrochemicals.
- Total FDI inflow in the chemical sector (other than fertilizer) reached USD 18.69 Bn between April 2020 and July 2021.



### INCREASING INVESTMENT

- India's specialty chemical companies are expanding their capacities to cater to rising demand from domestic and overseas.
- PCPIRs are expected to attract investments worth 7.63 Lakh Crs (USD 104.36 Bn)



# FINANCIAL OVERVIEW

# Historical Consolidated Income Statement

Particulars (INR Mn)	FY19	FY20	FY21*	FY22*
Operational Income	6,923	6,749	7,548	11,533
Total Expenses	5,125	4,946	5,496	9,484
EBITDA	1,798	1,803	2,052	2,049
<i>EBITDA Margins (%)</i>	<i>25.97%</i>	<i>26.71%</i>	<i>27.19%</i>	<i>17.77%</i>
Other Income	87	63	59	74
Depreciation	136	158	212	296
Finance Cost	37	23	50	65
<b>PBT</b>	<b>1,712</b>	<b>1,685</b>	<b>1,849</b>	<b>1,762</b>
Tax	500	423	540	483
Profit After Tax(Before merger)	1,212	1,262	1,309	1,279
Impact of Scheme of Merger	120	-	-	-
<b>Profit After Tax (After Merger)</b>	<b>1,332</b>	<b>1,262</b>	<b>1,309</b>	<b>1,279</b>
<i>PAT Margins (%)</i>	<i>19.24%</i>	<i>18.70%</i>	<i>17.34%</i>	<i>11.09%</i>
Other Comprehensive Income	-	2	69	6
<b>Total Comprehensive Income</b>	<b>1,332</b>	<b>1,264</b>	<b>1,378</b>	<b>1,285</b>
Diluted EPS (INR per share)	95.29 <sup>^</sup>	44.32	40.97	40.51

\*FY21 onward figures as per Ind AS

FY 2018-19 figures are basis IGAAP accounting standards and hence are not directly comparable with other periods

<sup>^</sup> Reduction in EPS is on account of issue of Bonus Shares during FY 2020 - 21. EPS for FY 2019 - 20 is restated accordingly

# Consolidated Balance Sheet

Particulars (INR Mn)	FY20	FY21*	FY22*
<b>EQUITY</b>	<b>4,007</b>	<b>5,086</b>	<b>6,489</b>
a) Equity Share Capital	121	272	272
b) Other Equity	3,736	4,747	5,856
c) Optionally Convertible Preference Shares	18	4	4
d) Non Controlling Interest	132	63	357
<b>LIABILITIES</b>			
<b>Non-Current Liabilities</b>	<b>992</b>	<b>971</b>	<b>1,340</b>
Financial Liabilities			
a) Borrowings	841	751	1,058
b) Lease Liabilities	-	2	5
c) Provisions	2	15	11
d) Deferred Tax Liabilities (Net)	149	203	266
<b>Current Liabilities</b>	<b>1,692</b>	<b>2,706</b>	<b>4,018</b>
a) Financial Liabilities			
(i) Borrowings	406	1,330	2,568
(ii) Trade Payables	879	1,072	1,238
(iii) Other Financial Liabilities	359	253	161
(iv) Lease Liabilities	-	4	3
b) Other Current Liabilities	13	21	24
c) Provisions	35	26	24
<b>GRAND TOTAL - EQUITIES &amp; LIABILITES</b>	<b>6,691</b>	<b>8,763</b>	<b>11,847</b>

\*FY21 onward figures as per Ind AS

Particulars (INR Mn)	FY20	FY21*	FY22*
<b>Non-Current Assets</b>	<b>4,451</b>	<b>5,731</b>	<b>6,652</b>
a) Property, Plant and Equipment	2,729	4,967	5,303
b) Capital Work In Progress	1,291	459	1,116
c) Right-Of-Use Assets	7	6	8
d) Goodwill	28	-	-
e) Goodwill on Consolidation	-	123	123
f) Financial Assets			
(i) Investments	181	23	33
(ii) Loans	61	59	58
(iii) Other Financial Assets	-	-	-
g) Other Non-Current assets	154	94	11
<b>Current Assets</b>	<b>2,240</b>	<b>3,032</b>	<b>5,195</b>
a) Inventories	449	722	1,136
b) Financial Assets			
(i) Investments	47	40	46
(ii) Trade Receivables	1,326	1,568	3,209
(iii) Cash and Cash Equivalents	77	128	251
(iv) Other Bank balances	50	182	203
(v) Loans	7	5	5
(vi) Other financial assets	-	2	3
c) Other Current Assets	242	363	233
d) Current Tax Assets (Net)	42	22	109
<b>GRAND TOTAL – ASSETS</b>	<b>6,691</b>	<b>8,763</b>	<b>11,847</b>



# Historical Standalone Income Statement

Particulars (INR Mn)	FY19	FY20	FY21*	FY22*
Revenue from Operations	6,060	5,836	5,742	9,484
Total Expenses	4,283	4,103	4,170	7,834
EBITDA	1,777	1,733	1,572	1,650
<i>EBITDA Margins (%)</i>	<b>29.32%</b>	<b>29.69%</b>	<b>27.37%</b>	<b>17.40%</b>
Other Income	64	52	169	56
Depreciation	118	130	186	273
Finance Cost	15	10	35	64
<b>PBT</b>	<b>1,708</b>	<b>1,645</b>	<b>1,520</b>	<b>1,369</b>
Tax	496	406	374	340
Profit After Tax(Before merger)	1,212	1,239	1,146	1,029
Impact of scheme of merger	120	-	-	-
<b>Profit After Tax (After Merger)</b>	<b>1,332</b>	<b>1,239</b>	<b>1,146</b>	<b>1,029</b>
<i>PAT Margins (%)</i>	<b>21.98%</b>	<b>21.23%</b>	<b>20.00%</b>	<b>10.85%</b>
Other Comprehensive Income	-	2	69	8
<b>Total Comprehensive Income</b>	<b>1,332</b>	<b>1,241</b>	<b>1,215</b>	<b>1,037</b>
Diluted EPS (INR per share)	95.29	44.32	40.98	36.81

\*FY21 onward figures as per Ind AS

FY 2018-19 figures are basis IGAAP accounting standards and hence are not directly comparable with other periods

^ Reduction in EPS is on account of issue of Bonus Shares during FY 2020 - 21. EPS for FY 2019 - 20 is restated accordingly

# Standalone Balance Sheet


Particulars (INR Mn)	FY20	FY21*	FY22*
<b>EQUITY</b>	<b>3,875</b>	<b>5,023</b>	<b>6,031</b>
a) Equity Share Capital	121	272	272
b) Other Equity	3,736	4,747	5,755
c) Optionally Convertible Preference Shares	18	4	4
<b>LIABILITIES</b>			
<b>Non-Current Liabilities</b>	<b>953</b>	<b>962</b>	<b>1,215</b>
Financial Liabilities			
a) Borrowings	808	748	940
b) Lease Liabilities	-	2	2
c) Provisions	2	15	10
d) Deferred Tax Liabilities (Net)	143	197	263
e) Other Non-Current Liabilities	-	-	-
<b>Current Liabilities</b>	<b>1,462</b>	<b>2,071</b>	<b>3,583</b>
a) Financial Liabilities			
(i) Borrowings	221	736	2,110
(ii) Trade Payables	840	1,042	1,271
(iii) Other Financial Liabilities	355	244	154
(iv) Lease Liabilities	-	3	2
b) Other Current Liabilities	13	20	22
c) Provisions	33	26	24
d) Current Tax Liabilities (Net)	-	-	-
<b>GRAND TOTAL - EQUITIES &amp; LIABILITES</b>	<b>6,290</b>	<b>8,056</b>	<b>10,829</b>

\*FY21 onward figures as per Ind AS


Particulars (INR Mn)	FY20	FY21*	FY22*
<b>Non-Current Assets</b>	<b>4,381</b>	<b>5,798</b>	<b>6,787</b>
a) Property, Plant and Equipment	2,525	4,771	5,085
b) Capital Work In Progress	1,291	459	1,102
c) Right-Of-Use Assets	3	4	4
d) Goodwill	28	-	-
(i) Investments in Subsidiaries	145	395	501
(ii) Loans	54	52	52
(iii) Other Financial Assets	181	24	32
j) Other Non-Current assets	154	93	11
<b>Current Assets</b>	<b>1,909</b>	<b>2,258</b>	<b>4,042</b>
a) Inventories	409	660	973
b) Financial Assets			
(i) Investments	12	1	1
(ii) Trade Receivables	1,108	1,166	2,532
(iii) Cash and Cash Equivalents	75	86	230
(iv) Other Bank balances	30	32	3
(v) Loans	6	5	5
(vi) Other financial assets	-	2	3
c) Other Current Assets	224	257	217
d) Current Tax Assets (Net)	45	49	78
<b>GRAND TOTAL – ASSETS</b>	<b>6,290</b>	<b>8,056</b>	<b>10,829</b>

# Consolidated Financial Highlights


### Operational Revenue (INR Mn)




### EBITDA (INR Mn) & EBITDA Margins (%)




### PAT (INR Mn) & PAT Margins (%)




### Net Debt to Equity (x)



### Net Worth (INR Mn)



### Return on Capital Employed & Return on Equity (%)




Share Price up to 31<sup>st</sup> March, 2022



Price Data (As on 31 <sup>st</sup> March, 2022)	INR
Face Value	10.00
Market Price	920.05
52 Week H/L	1,845/ 794.7
Market Cap (Mn)	24,982.57
Equity Shares Outstanding (Mn)	27.15
1 Year Avg Trading Volume ('000)	84.40

Shareholding pattern (As on 31<sup>st</sup> March, 2022)



## **Valiant Organics Limited**

*No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Valiant Organics Limited ("Company"), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.*

*Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.*

*This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.*

*This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.*

## **Valorem Advisors Disclaimer:**

*Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.*

*Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.*



**For further details please contact our Investor Relations Representatives:**

**VALOREM ADVISORS**

**Mr. Anuj Sonpal**

Tel: +91-22-49039500

Email: [valiant@valoremadvisors.com](mailto:valiant@valoremadvisors.com)





**THANK YOU**